Company news
Sensei Biotherapeutics, Inc. news in 2023
Sensei Biotherapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 6, 2023
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
November 2, 2023
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
October 31, 2023
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
October 24, 2023
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
October 22, 2023
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
September 26, 2023
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
September 20, 2023
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Im...
September 12, 2023
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
August 29, 2023
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 2, 2023
Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
August 1, 2023
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
June 12, 2023
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
May 31, 2023
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 8, 2023
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
April 19, 2023
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
April 17, 2023
Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
March 29, 2023
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
March 27, 2023
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
March 20, 2023
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 13, 2023
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
March 6, 2023
Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
March 5, 2023
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
February 20, 2023
Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit
February 15, 2023
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
February 13, 2023
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
February 5, 2023
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
January 4, 2023
Decks in 2023
- Investor Presentation (November 2023)
Investor deck · 40 slides · Nov 3, 2023
- Technical Presentation (June 2023)
Technical · 32 slides · Jun 27, 2023
- Investor Presentation (April 2023)
Investor deck · 34 slides · Apr 20, 2023
- Investor Presentation (March 2023)
Investor deck · 33 slides · Mar 13, 2023